10 Best Healthcare Stocks For Long-Term Investment

6. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Holders: 42 

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company specializing in treatments for rare and life-threatening diseases, primarily pulmonary arterial hypertension (PAH) and cardiovascular disorders. Its key medications—Remodulin, Tyvaso, and Orenitram—are sold to patients, hospitals, and specialty pharmacies.

United Therapeutics Corporation (NASDAQ:UTHR) ended 2024 with record revenue and strong earnings, surpassing expectations. The company reported earnings per share (EPS) of $6.19, beating estimates of $6.10. Double-digit growth in key products, including Tyvaso, Remodulin, Orenitram, and Unituxin, contributed to the financial success.

United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue grew 19% year-over-year to $4 million in Q4, while Orenitram saw a 28% increase to $108 million. Remodulin generated $135 million in worldwide revenue, up 17%, and Unituxin achieved record revenue of $68 million, reflecting 25% growth. These gains highlight the corporation’s strong market position in treating pulmonary arterial hypertension (PAH) and other rare diseases.

In addition to financial growth, United Therapeutics Corporation (NASDAQ:UTHR) advanced its clinical pipeline. The company received IND clearance for the uKidney clinical trial, marking the first FDA-cleared xenotransplantation trial for organ replacement. Capital allocation remains balanced between strategic investments, acquisitions, and shareholder returns through repurchase programs, reinforcing confidence in sustained growth and innovation.